Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Trastuzumab in HER2+ Breast Cancer (N9831)
NCT00005970Phase 3Completed
- Sponsor
- National Cancer Institute
- Start
- May 2000
- Primary completion
- Apr 2005
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 4
01
Overview
A Phase 3 trial of trastuzumab in breast adenocarcinoma, sponsored by National Cancer Institute. Started May 2000; status: completed.
02
Drugs
03
Conditions
breast adenocarcinoma
Beyond the preview
Go deeper on NCT00005970.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00005970.